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Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those
not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the
goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN)
are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor,
which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites,
highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern
Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight
into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary
team, tailored towards each patient’s profile and their expectations, by drawing upon scientific evidence coupled with experience.
Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute’s DBS paradigm
to ensure that patients receive the optimal therapy.
1. Historical Perspective
Therapeutic targets for ameliorating the disabling symptoms
of Parkinson disease, namely, tremor, were discovered early in
the 20th century by neurosurgical observations, leading to an
era of ablative procedures targeting the basal ganglia, refined
further by advancements such as stereotactic surgery. The
advent of levodopa therapy in the 1960s resulted in a decline
in surgical management; however, the eventual emergence
of side effects and suboptimal control of medication related
phenomena such as dyskinesias and motor fluctuations have
renewed the interest in surgical interventions [1]. While the
use of electrical stimulation of the nervous system for pain
control and seizures has been in play from the early part of
the 20th century, the role of DBS in Parkinson disease can
be traced to the outpatient stimulation of the thalamus and
globus pallidus for motor disorders in 1972 by Bechtereva,
to the first implanted stimulator for tremor in a Multiple
Sclerosis patient in 1980 by Brice and McLellan, and last
but not least to the first reported case of DBS in Parkinson
disease at the ventral intermediate nucleus of the thalamus
in 1987, by Dr. Benabid’s group in France [2, 3]. This was
followed by a rapid exploration into the potential of DBS,
resulting in a field continuously evolving and improving
in its technique, technology, knowledge, and mandate [4].
The evolution of therapies for Parkinson disease involves
an incredible journey of collaboration between clinical and
basic sciences. A fortuitous observation linking Parkinsonian
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symptoms in young drug users resulted in the identification
of MPTP [5], with the subsequent development of animal
models [6] which allowed robust experimentation and proof
of therapeutic targets for Parkinson disease [7–9].
2. Introduction and Evolution of the Program
The Deep Brain Stimulation program at UT Southwestern
Medical Center in Dallas began in 1998 following FDA
approval of DBS (in 1997 for essential tremor and 2002
for Parkinson disease), with steady growth in the number
of procedures performed, up to 45 per year in 2016. The
rapid evolution of the program mirrors the data available
through various large studies, on the benefits of DBS versus
medical therapy alone. Two landmark clinical trials [10,
11] demonstrated the efficacy of DBS over best medical
management in improvingmotor functions, on-time without
dyskinesias, and quality of life at 6 months, which have
to be weighed against an increased risk of serious adverse
events. While DBS does cause a significant improvement in
motor scores as compared to medical management, this does
not always translate into an improved quality of life, since
complications associated with DBS surgery such as seizures
and negative effects of DBS on cognition and mood may not
allow themotor gains to be perceived andmay in fact decrease
quality of life. At UTSW, as part of a continuous quality
improvement process [12], the DBS program collects data on
both motor improvement and quality of life for analysis of
patient outcomes, which will allow us as an institution to
track our performance and ensure the best possible results.
Medical decision-making represents the art and science
of weighing evidence based information with practice pref-
erences, both comfort and experience, and target selection
for DBS in Parkinson disease patients is no different. The
availability of several studies and analyses on this topic,
including some randomized controlled and blinded trials
which allow a higher level of confidence in their results,
provides objective and up-to-date information, which equips
physicians to exercise greater scientific rigor into their
decision-making process and importantly enables patients to
consent with relevant prognostic data.
3. Target Sites
The main targets for DBS in Parkinson disease are GPi
(Globus Pallidus Interna) and STN (Subthalamic Nucleus),
with the balance between the two tilting back and forth in
light of new evidence. This decades-long duel has its origins
in the pallidal preference for ablative procedures which was
swiftly replaced by an overwhelming preference for STN
when several prominent studies backed its superiority [13, 14].
The first study with a side by side comparison of the two sites
in 2001 showed significant motor benefits of DBS therapy at
either site and led to its FDA approval for Parkinson disease.
While this study was not designed to compare the two sites
in theory, the authors set the precedent for STN preference
[15].This penchant towards STN inDBShas been reexamined
in several rigorous trials [16–18] which did not uphold its
dominance, allowing a “rematch” as aptly termed [19, 20].
These reports have culminated in a consensus in the field to
move away from a ‘one size fits all’ use of STN for the disease,
to a target choice which is tailor-made to a patient’s specific
symptoms and profile.
4. Site Selection
At UTSW, the target for DBS surgeries for patients of
Parkinson disease is selected during the neuromodulation
committee meeting, a multidisciplinary board compris-
ing neurologists (movement disorders specialists), neuro-
surgeons, a dedicated DBS coordinator, speech language
pathologists, physical therapists, and neuropsychologists.
This process requires a comprehensive list of preselection
tests, scales, and procedures in addition to motor scoring
such as preoperative neuropsychological testing, brain MRI,
physical therapy assessment, speech, and swallow assessment,
to determine eligibility and site and maintain a baseline
record of parameters to compare outcomes [12]. In terms of
symptom alleviation, patients are selected to undergo DBS
based on their response to levodopa. A levodopa challenge
test, with an improvement of 30% on the UPDRS III (Unified
Parkinson Disease Rating Scale, motor score), is accepted as
the best predictive factor for successful DBS outcomes [21].
At UTSW, this motor scale is performed and videotaped both
off medications and after an effective dose of levodopa. It
is important for patients to be counseled on the expected
results of DBS on each of their symptoms (both positive
and negative) in order to align patient expectations with
outcomes. It is at this monthly meeting that patients’ history
and test results are reviewed to ensure suitability for the
DBS procedure, and if so, what the optimal target would
be, based on the symptom profile and operative constraints
if any. This inclusive, multispecialty, on-the-spot input is
invaluable for a comprehensive assessment, with a thorough
evaluation of the risk-benefit ratio for each unique case.
This meeting incorporates relevant and recent studies in its
decision-making to ensure scientific due diligence, reflected
by the due process followed at UTSW to evaluate patients
on a case by case basis, moving away from the global trend
of STN as the site for DBS. We have performed 30 surgeries
with GPi as the target and 28 with STN target through our
DBS program, with an overlap occurring due to switching
or addition of the other target site for enhanced symptom
control. Over the last 2 years, these numbers are 22 with GPi
as the target and 18 with the STN target.
5. Comparison of the Target Sites
A comparison of the two targets encompasses various param-
eters, such as therapeutic benefits, mechanisms of action, and
adverse effects.
5.1. Anatomy. The anatomical differences between the two
sites, namely, their size and location, are the basis for some of
the observed differences.TheGPi is roughly 3 times the size of
STN and thus requires a higher charge density. Studies show
that the DBS stimulation settings in patients with pallidal
stimulation are significantly higher in amplitude and pulse
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width as compared to STN stimulation (with no difference
in frequency) which results in more frequent battery changes
and higher opportunity for surgical complications [16, 22,
23]. However, the disadvantages of stimulation applied to a
compact target such as the STN include a spread of current to
neighboring circuits, resulting in increased number of stim-
ulation related adverse effects. The smaller size of the STN
makes it harder to place the leads exactly in the designated
sensorimotor areas, possibly overlapping with the limbic or
associative areas of the STN and could be responsible for the
various cognitive and psychiatric side effects by activation of
nonmotor circuitry [20].
5.2. Symptoms
5.2.1. Motor Symptoms and On-Off Period. Motor control is
the primary treatment goal of Parkinson diseasemanagement
and both GPi and STN-DBS equally improve motor function
[24, 25]. The UPDRS III is used universally as a scale to
measure the motor improvement after DBS and is assessed
in varying combinations, with medication off and on and
stimulation off and on. In a randomized trial conducted
to compare DBS at the 2 sites at Veterans’ Affairs and
university hospitals (the Veterans Affairs Cooperative Studies
Program), themotor improvements withmedications off and
stimulation on showed no statistical difference between the
effects of DBS at either target at time periods extending out to
24months [16] and 36months [17]. Both time periods showed
a slightly higher improvement with the pallidal target and a
slight worsening with STN-DBS when both medications and
stimulation were on. However, this effect was exaggerated
(pallidal improvement and STN deterioration) when both
medications and stimulation were off. Different studies show
conflicting results: a randomized trial with a 1-year follow-up
period (NSTAPS) showed a greater change in motor scores
in the medication off phase with STN-DBS versus GPi [23],
with the 3-year follow-up showing the same result [22], but
no differences between the 2 sites in themedication on group.
Themajor advantage with DBS is the amount of time spent in
the “on” versus “off” period, a significant disability faced by
patients managed medically. While most studies confirm this
advantage and peg it at 4–6 hours of time saved from the “off”
phase, with no difference between the STN orGPi sites, this is
a measure usually tracked by the patients themselves through
a diary and/or part IV of the UPDRS which does not always
allow a rigorous analysis [20].
At UTSW, the DBS coordinator utilizes several scales to
assess the motor performance both prior to the procedure
and at follow-up visits. This includes parts 1–4 of the Unified
ParkinsonDiseaseRating Scale, with part 3 performedon and
off medications in the following combinations: stimulation
off, medications off; stimulation on, medications off; and
stimulation on, medications on. Specific tests are used for
DBS performed for nonparkinsonian conditions such as
essential tremor or dystonias.
5.2.2. Tremor. With respect to individual symptoms, resting
tremor responds successfully to both GPi and STN-DBS
[20, 26]. It is postulated that tremor may be more effectively
controlled with STN-DBS in part due to the size of the
nucleus allowing a more complete stimulation-coverage of
the area, whichmay be insufficient for the larger GPi [19].The
exact location of the leads within these nuclei is being studied
for optimal tremor control. While the resting tremor is often
suppressed, a coexisting essential tremor may progressively
worsen with time, which could be addressed by using the
posterior subthalamic area (PSA) as a target site [27] or
the ventralis intermedius (VIM) nucleus, often used as an
additional site for suppression.
At UTSW, an interesting case report of a patient who
did not experience optimal tremor control with bilateral
STN-DBSwas presented at the ANA (AmericanNeurological
Association) in 2015 and is possibly the first case of uni-
lateral GPi lead rescue for tremor due to STN failure and
stimulation related side effects [28]. The patient was a 59-
year-old right handed man with a diagnosis of Parkinson
disease made at UTSW 6 years ago, who presented for
DBS evaluation with severe right sided tremors (the initial
symptoms) andmilder left sided tremors affecting both upper
and lower extremities along with other typical Parkinsonian
symptoms such as rigidity and bradykinesia (predominantly
right sided), hypophonia, stuttering speech, and slow gait.
Due to disabling tremors refractory to optimal medical
management, the patient opted for bilateral STN-DBS within
2 years and initially experienced nearly complete resolution
of his right sided tremors. However, he could not tolerate
the long-term side effects of stimulation such as tingling,
numbness, and incoordination along with an eventual loss
of left sided tremor control; in addition, the patient stopped
taking his medications due to meager benefit and adverse
effects. Neuroimaging demonstrated a misplaced lead on the
right side which could be responsible for the stimulation
related adverse effects (SAEs). The patient, limited by his
medication intolerance and symptom resistance, consented
to undergo another DBS procedure, a right sided unilateral
GPi rescue lead with the expectation of better tremor con-
trol with the alternative target. Postoperative programming
resulting in optimal tremor control especially on the left
could be achieved with dual right sided (both STN and
GPi) along with left-STN stimulation. While there are a
few recent case reports of GPi-DBS serving as a “rescue”
lead for symptoms such as dystonia, behavioral features, and
dyskinesias in patients with STN-DBS [29, 30], this particular
case serves as an example for the use of GPi rescue leads
for a STN-DBS refractory tremor. The addition of rescue
GPi leads reflects possible mechanistic differences, such as
complementary activation of the GPi, aside from its indirect
stimulation via STN-DBS.The supplementary GPi lead could
allow the activation of additional motor pathways which may
not be accessed via the STN, without concurrent stimulation
of limbic and associative fibers, thus eliminating unnecessary
side effects, along with an element of its inherent efficacy for
the alleviation of a symptom such as dystonia [28, 30].
5.2.3. Rigidity and Bradykinesia. Rigidity and Bradykinesia
aremotor symptoms that respondwell to DBS at both targets.
A study (COMPARE trial) showed greater improvement in
rigidity with a unilateral STN-DBS lead versus GPi lead at
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a 7-month follow-up time point [26] but no such significant
advantage between the two sites could be found in bilateral
DBS studies at 6 months [17] or 12 months [18]. While most
studies do not show a difference between the target sites
for improvement in bradykinesia [17, 26], some studies have
shown an advantage of STN stimulation [18, 31].
5.2.4. Dyskinesia. Dyskinesia suppression is achieved at
either target through fundamentally different mechanisms,
direct stimulation effects of GPi-DBS and medication reduc-
tion in STN-DBS. This difference is responsible for the
dyskinesia suppression in STN-DBS in the absence of active
stimulation contrasted to GPi-DBS, which requires active
stimulation for dyskinesia control at 3 months. However,
dyskinesia control in GPi-DBS can be seen at 12 months
even with stimulation off and can be attributed to long-
term effects on dopaminergic pathways [18]. While a study
reported a difference between bilateral GPi versus STN-DBS
(89% versus 62% improvement in dyskinesia, resp.), it was
not significant [18], but it went on to set the precedence of
accepting GPi as superior in dyskinesia reduction [19]. STN-
DBS has been associated with an exacerbation of dyskinesias
[25] and “brittle dyskinesias” unamenable to control by
optimizing programming and medication, requiring rescue
surgery with GPi [32]. The superior suppression of dyski-
nesias, independent from medication, allowing flexibility in
dose adjustment (to prevent dose-reduction side effects) and
the absence of extraneous dyskinesias put GPi in the lead for
patients with predominantly dyskinetic symptoms.
While motor manifestations of Parkinson disease are
often well managed medically and with DBS, there is a
shift in the patient experiences towards other often disabling
abnormalities of gait, posture, speech, cognition, mood,
and autonomic disturbances, all of which are important
determinants of quality of life.
5.3. Cognition. A decline in cognition significantly affects
quality of life and is seen both in the natural progression of the
disease and afterDBS.The effects of DBS on cognition,mood,
and behavior are extensively studied, with most studies
revealing lower abnormalities after GPi-DBS as compared to
STN-DBS, largely responsible for the “rematch,” a shifting
away from the STN only approach.
The issues concerning cognition and DBS are multifold.
Cognitive risk factors in patients do not serve as blanket
exclusion criteria for surgery; rather they influence patient
counseling for postoperative expectation setting and pos-
sibly target selection. Patients with preexisting dementias
are usually disqualified from DBS surgery due to risk of
worsened cognitive outcomes [33, 34]. However, in patients
with mild cognitive changes, the decision to undergo DBS is
a risk-benefit analysis between improved motor symptoms
and likely cognitive worsening, which may in turn impact
the overall ability to function and quality of life. Issues of
competency to consent for this invasive procedure as well as
the ability to participate during the surgery itself and keep
up with the extensive follow-up testing are brought to the
forefront in patients with diminished cognitive reserve.
At the 24-month follow-up of the Veterans Affairs Coop-
erative Studies Program, to compare bilateral DBS at both
targets, results showed a slight decrease in neurocognitive
function in both groups with a significantly greater decline
in processing speed in the STN group, especially in the
visuospatial domain [16]. At 36 months, this effect was
maintained, albeit the Parkinson Disease Questionnaire-
39 (PDQ-39) cognition subscale scores did not reach a
significant difference betweenGPi and STN.However, testing
such as the Mattis Dementia Scale and measures of verbal
fluency (the Hopkins Verbal Learning Test) did show a
significant difference between the two sites (favoring GPi)
[17]. A long-term (10-year follow-up) study of STN-DBS
demonstrated a 46% prevalence of dementia in patients,
with no relationship to mortality, occurring about five and
a half years after the surgery. It must be kept in mind that
dementia is a known nonmotor complication of Parkinson
disease with an overall prevalence of about 40% and this
reaches as high as 83% in patients who have the disease
for over 20 years [35]. The presence of dementia is heavily
linked to the age of patients, thus making age of onset of
Parkinson disease a compounding factor while comparing
dementia prevalence after certain duration of disease. This
could explain why the latter long-term study (where patients
had early-onset disease) did not show as high as previously
observed dementia due to skewing of the data [36]. Another
randomized trial that compared the two sites with unilateral
stimulation, with a specific emphasis on mood and cognition
(COMPARE), demonstrated no changes between the two
sites in semantic fluency but a greater decline in letter fluency
in the STN group, which did not reach their predetermined
level of significance [26]. This study also demonstrated that
the decline in letter fluency in the STN groupwas irrespective
of stimulation setting (location) as compared to GPi. A
meta-analysis of the effects of DBS on cognition showed
small decreases in overall cognition as well as in domains
such as memory, attention, executive function, psychomotor
speed following STN-DBS, and moderate decreases in verbal
fluency both semantic and phonemic. GPi-DBS on the other
hand showed only a small deficit in attention and verbal
fluency [37]. This superior effect of GPi on cognition has
to be balanced by the conflicting data from the 24- and
36-month follow-up of a trial (NSTAPS) which shows no
statistical difference between the 2 sites on a composite score
encompassing adverse effects of behavior, cognition, and
mood [22, 23].
A randomized trial using bilateral STN stimulation with
a constant current device had an interesting and seminal
finding that the decline in verbal fluency noticed after STN-
DBS occurred in both the activated (stimulation turned on)
and inactive leads (implanted but never activated) allowing
one to infer that these effects are likely due to surgery itself
and possibly the surgical trajectory rather than specifically
STN-DBS [38].
Relying solely on cognitive screens is not always ade-
quately sensitive to detect the often subtle postoperative
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cognitive changes, which require an in-depth neuropsy-
chological assessment consisting of a wide array of tests
spanning all domains [39]. UTSW has taken the approach of
gathering extensive data through a battery of tests adminis-
tered by a qualified neuropsychologist prior to surgery. The
preoperative tests include cognitive tests, tests of executive
function, tests for attention and processing speed, language
testing, memory test, visuospatial tests, and testing mood
and behavior. Scores from each test are converted to a
global score as well as individual domain scores, which
along with qualitative analysis are used to prepare a graph
enabling an easy visual interpretation of data at the monthly
committee meeting. Postoperatively, cognitive function is
tracked through theMontreal CognitiveAssessment (MoCA)
and this alongwith surgical complications,motor, and quality
of life data are discussed at the outcomes review meeting.
This ensures that patients with suboptimal outcomes are
immediately identified and corrective action, if any, can be
undertaken [12].
However, despite preoperative cognitive screening, sev-
eral patients go on to develop cognitive dysfunction including
dementia, often within 6 months of surgery [34, 39, 40].
While dementia is part of the natural progression of the
disease, surgery likely plays a precipitating role. Cases have
been reported of immediate postoperative cognitive decline
following STN-DBS, often associated with suboptimally
placed leads [41, 42]. At UTSW, we have identified two such
patients who presented with disabling cognitive symptoms
soon after DBS [43].
A 67-year-old male patient living with Parkinson disease
for 7 years with normal preoperative cognition underwent
bilateral STN-DBS. Apart from mild global atrophy, minor
word-finding difficulties, and slowed thinking, he could
independently manage his finances and medications. After
an uneventful surgery, he experienced relief of motor symp-
toms and had his medications reduced; however, cognitive
changes were noticed by his family within a matter of days.
He experienced prominent memory and executive func-
tion declines, including impulsiveness, disinhibition, poor
judgment, and inappropriate behavior. His REM behavior
disorder symptoms worsened and he was frequently angry.
Neuropsychological testing after 2 months revealed frontal
lobe dysfunction with significantly reduced problem solving,
attention, memory, and phonemic fluency, compared to
preoperative levels, unchanged by increasing his levodopa
dose. Similar testing 14 months after surgery revealed global
cerebral dysfunction, with major involvement of the frontal
lobes, consistent with dementia. He was evaluated for unde-
termined spells for which EEG did not reveal abnormalities
and was subsequently treated for orthostatic hypotension.
The second patient was a 57-year-old man with Parkinson
disease for 9 years, who underwent bilateral STN-DBS. He
was preoperatively found to have mild global atrophy, past
history of medication induced hallucinations, practically
minor problems with memory, and mild frontal-subcortical
cognitive deficits on testing, which were stable over a year.
He experienced confusion after an uneventful surgery, which
worsened after the battery placement. Despite motor bene-
fits, he became inattentive and disoriented, with worsening
anxiety. Neuropsychological testing 3 months after surgery
revealed global decline, with prominent frontal-subcortical
involvement, consistent with mild to moderate dementia.
In both cases, a medical work-up was unrevealing and
MRIs taken 1 month postoperatively did not show any signs
of infection, hemorrhage, or infarct. A study of the lead
trajectory revealed they all passed through the frontal lobe,
lateral ventricle, and posterior-medial border of the STN,
with the lead in Patient 1 travelling further caudal towards the
midbrain-pontine junction after a year. The lead positions in
the first patient were noted to be posterior-medial in the STN,
rather than in the dorsal STN for optimal motor benefit, and
at a much greater than intended depth. Turning the stimu-
lation off for a few weeks did not halt the cognitive decline
in the patients, which the authors suggest to be attributed
to the lead positions, its trajectories, and the surgery itself
hastening the process [43]. This highlights the necessity of
stringent preoperative screening and counseling in patients
with mild cognitive impairment undergoing DBS as both
hallucinations albeit medication related and prior cognitive
impairment (as seen in the second patient) are risk factors for
this adverse outcome [40]. The quality improvement project
has identified this as an area that would benefit from cycles of
plan-do-study-act. With adequate postoperative MRI scans,
it is possible to correlate clinical outcomes with lead locations
and trajectories. This along with neurosurgical input would
allow a plan to ensure more accurate lead placement and
localization [12].
5.4. Mood and Behavior. Several patients experience stim-
ulation related changes in mood and behavior such as
depression, hallucinations, impulse control disorder, apathy,
and dopamine dysregulation syndrome.These adverse effects
may be related to preexisting psychiatric illnesses, stress,
medication reductions, surgery-related factors, changes in
social situations following surgery, and mismatched patients’
expectations versus outcomes [34]. While these occur in
patients of both STN and GPi-DBS, several studies have
shown a preponderance of negative effects on these parame-
ters with STN-DBS. A study of 24 patients with bilateral STN-
DBS revealed that careful selection of patients was required to
enjoy the motor benefits of DBS. A preponderance of anxiety
and emotional hyperreactivity after surgery along with other
undesirable behavioral side effects and maladjustment to the
family or social environment resulted in unsatisfied patients,
despite motor improvements [44].
A trial to compare the effects of unilateral DBS at the STN
and GPi, specifically on mood and cognition (COMPARE
trial), gathered data on the impact of DBS using Visual
AnalogueMood Scales (VAMS) with several subscales. Seven
months after surgery, there were an overall reduction of
tiredness in both groups and improved scores in “feeling
happy” and “less tense”; however, feelings of anger, confusion,
and irritability increased. There was no significant difference
between the two sites in these subscales of mood, except
for an increased anger in the STN group [26]. Based on
the position of the leads in this study, the most undesirable
outcome (less happy and energetic, more confused, and sad)
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occurred in a ventral stimulation setting at both sites, which
could be a possible explanation for patients who suffer severe
mood changes due to incorrect lead placement.
TheBeckDepression Inventory II, used as ameasurement
tool, showed an improvement in the GPi group contrasted
to a decline in the STN group [17], with similar findings
by a meta-analysis showing greater improvements in this
scale in the GPi group [25]. However, the former study
(Veterans Affairs Cooperative Studies Program) showed that
the differences between the two sites disappear by 36 months
[18]. While most studies concur on the greater negative
outcomes of STN-DBS on mood and behavior, a randomized
and blinded trial (NSTAPS), on the contrary, demonstrated
no differences between theGPi and STN in a composite score,
designed to measure various aspects of mood, cognition, and
behavior, and the findings remained constant at the 12-month
and 36-month follow-up [23, 24].
Changes such as delirium, hallucinations, anxiety, hypo-
mania, and apathetic mood have been noted in the periop-
erative period, in patients who underwent STN-DBS with
no similar changes noted in patients who underwent GPi
stimulation [18].While perioperative changes usually resolve,
the existence of hallucinations prior to surgery must be
evaluated while determining eligibility for the procedure.
Drug-induced hallucinations are expected to improve due to
dosage reductions made possible after STN-DBS, but those
due to the disease itself are worsened and usually serve to
exclude patients from the procedure. In a long-term (10
years) follow-up of STN-DBS patients, hallucinations were
present in nearly 60% of the group. These hallucinations
occurred approximately 4 years after the surgery, were asso-
ciated with a higher mortality and the use of antipsychotics,
and, importantly, showed no significant difference in the
dopaminergic medication doses in those suffering from
psychotic symptoms versus thosewho had no such symptoms
[36].
There is a wide range of effects of DBS on impulse
control disorders (ICD), ranging from complete resolution
of preexisting disorders partial resolution and generation of
new ICDs after DBS. A study following a group of patients
with bilateral STN stimulation patterned the above, with
23% of the cohort having preexisting ICDs, of which 84% of
them benefited from their resolution after DBS, and the rest
had an appearance of new eating disorder symptoms. There
is a strong association between dopaminergic medication
dose and ICD occurrence, strengthened by the observation
that reducing medications after STN-DBS correspondingly
reduces the incidence of ICDs; however, this cannot explain
the occurrence of new ICDs in patients with already reduced
doses of medication following DBS. Of the cohort that did
not have preexisting ICDs, 14% developed them transiently,
a year after surgery, lasting for about 15 months, all of
which disappeared at the 3-year follow-up.Compulsive eating
disorders were the most frequently seen behavior after STN-
DBS and could account for the weight gain seen after
STN-DBS [34, 45]. The physiology of impulsiveness due to
dopaminergic drugs is different from stimulation effects of
STN-DBS and could be responsible for the new symptoms.
Attempts to stabilize ICDs should be undertaken prior to
the procedure, as DBS while providing relief in certain cases
cannot be used as an indication for surgery [20].
A large concern with the neuropsychological changes
seen after DBS is the increased possibility of suicide following
STN-DBS.While suicide (attempts and completed) have been
observed [34], a large study examining this did not show
a statistically significant difference in the onset of suicidal
ideation between the group treated with DBS as compared
to the group treated with best medical therapy (1.9% for DBS
versus 0.9% for BMT) [46]. This held true while comparing
the suicidal ideation between patients randomized to STN
or GPi-DBS at 6 months (1.5% versus 0.7%, resp.), albeit
several of the proxy symptoms were worse in the STN
group. The reasons for this are multifold: medical and neu-
rological conditions and complications related to the disease
and surgery, the often drastic reduction of dopaminergic
medication (possibly accounting for the decreased risk in
GPi-DBS), the preexistence of psychiatric comorbidities such
as depression, and the change in impulsivity, all of which
play a role in increasing the risk of suicidal ideation. This
reiterates the need for careful preoperative neuropsycholog-
ical assessment, continuous monitoring of depression, and
careful observation for the emergence of impulsive behaviors
and warning symptoms by family members.
A study analyzing the subjective or patient-perceived
benefits following STN-DBS revealed negative outcomes in
spite of almost universal motor benefits in patients who
underwent bilateral STN-DBS.Older age and longer duration
of disease were not associated with perceived negatives out-
comes; rather, the main predictors were axial symptoms and
apathy [47]. This study highlights apathy as the single most
important contributing factor towards subjective negative
outcomes after DBS, significantly higher in these patients
at baseline (prior to DBS surgery) as well as at the 12-
month follow-up, with similar findings for depression. The
aggravation of apathy in patients receiving stimulation is
independent of any changes in depression or cognition and
could be related to stimulation adverse effects or medication
reduction. While patients are usually counseled that their
axial symptoms would not be controlled by DBS, they are
often perceived to have worsened, which may be in part due
to their progression after surgery or that patients focus on
them upon resolution of other motor symptoms.This in turn
affects the quality of life scores and their own perception
of benefit after surgery, highlighting the absolute need for
setting expectations with the patient and their caregivers
clearly and repetitively.
Possible explanations for the greater deterioration of
cognitive and psychological parameters in STN-DBS patients
include the effects of anatomical size and medication reduc-
tion. Leads placed in the STN may spread the current
into the associative and limbic regions of the nucleus as
well as areas such as lateral hypothalamus, zona incerta,
and medial forebrain bundle, all of which have extensive
limbic connections. The role of dopaminergic medications
which are dramatically reduced in STN-DBS patients but
relatively maintained in GPi patients may play a part in the
latter’s cognitive advantage. This framework can be applied
to understand impulse control disorders as an imbalance
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between excess of dopamine with stimulation of limbic
circuits leading to their hyperactivity [21]. This necessitates
a balance between reducing the dosage of medication and
increasing the intensity of stimulation. A study of bilateral
STN-DBS patients observed that it is possible that certain
depressive disordersmay be unmasked after the surgery itself.
Patients with previously undiagnosed or unnoticed behav-
ioral disorders experienced a decompensation after STN-
DBS.This again highlights the need for extensive preoperative
neuropsychological counseling, delving into relevant topics,
such as present or remote addictive behaviors, personality
disorders, and depressive disorders, and, importantly, an in-
depth examination of the sociofamilial environment of the
patient [44].
At UTSW, mood and behavior are evaluated with cog-
nition prior to the procedure and at follow-up visits, as
explained above. The battery of tests includes the Beck
Depression Inventory II, the Questionnaire for Impulsive-
Compulsive Control Disorders in Parkinson disease-Rating
Scale (QUIP-RS), and the Quick Inventory of Depressive
Symptoms (QUIDS). Mood and behavior changes are also
captured in the quality of life data which is reviewed at
follow-up meetings, albeit there is lack of formalized testing
in these domains in the absence of patient complaints or
adverse events. Armed with this knowledge, it is imperative
that patients’ caregivers play an active and ever-vigilant role
in the assessment for subtle changes in the patient's mood,
behavior, and affect, after the DBS procedure. At UTSW,
we have incorporated realistic expectation setting in our
preoperative consent forms [12] clearly explaining which
symptoms are likely to improve, which ones are not expected
to improve, and possible side effects. However, it is in our
interest to ensure and recheck that the patients and their
caregivers have a complete understanding of these points and
are not overwhelmed by the extent of testing or holding on to
unrealistic expectations.
5.5. Quality of Life. The aim of all therapy is to ultimately
improve quality of life for patients; this especially holds
true for interventions such as DBS which are invasive and
expensive and potentially have serious adverse effects. While
controlling the motor symptoms of Parkinson disease is the
primary goal of medical and surgical therapy, nonmotor
symptoms such as mood, cognition, sleep, autonomic dys-
function, speech, and swallowing deficits form a large part of
the disease burden and are important determinants of quality
of life. These symptoms are more often than not resistant
to medical and DBS therapy and often negatively impact
patients’ perception of therapy, despite the control of the
cardinal motor symptoms.
Parkinson Disease Questionnaire, PDQ-39, is almost
universally used as a measure of quality of life across 8
domains or subscales: mobility, activities of daily living,
emotionalwell-being, social support, stigma, cognition, com-
munication, and bodily discomfort.
A trial comparing bilateral DBS at the 2 sites (NSTAPS)
did not find a significant difference in the quality of life
measured through the Parkinson disease quality of life
questionnaire-PDQL, not only at the 12-month follow-up
but also at the 36-month follow-up [22, 23]. The Veterans
Affairs Cooperative Studies Program after 24 months found
the quality of life as measured by the PDQ-39 improved in
most domains in both groups, with no significant differences
between them. Although there was a minor deterioration in
communication in both groups and worsened social support
after pallidal stimulation versus improved support after sub-
thalamic stimulation, these were not statistically significant,
with an overall positive impact on quality of life [16]. How-
ever, by 3 years, these quality of life gains were diminished,
with scores returning to baseline in certain domains such as
emotional well-being, social support, and cognition, with no
differences between the 2 sites [17]. Activities of daily living
followed a very similar trend, which did not show sustained
gains at 3 years after DBS, despite motor improvements. This
loss of benefit is important to note while counseling patients
on DBS. A randomized trial studying the effects of unilateral
DBS GPi versus STN on mood and cognition allowed an
in-depth analysis on the impact across various subscales of
quality of life, 6 months after surgery [48]. With similar
improvements in motor and mood symptoms, patients who
underwent GPi-DBS reported a significantly higher quality
of life as compared to those who underwent STN-DBS, with
both groups showing improvement in 6 subscales (mobil-
ity, activities of daily living, emotional well-being, stigma,
cognition, and bodily discomfort) but not on social support
or communication. The level of depression measured by the
BeckDepression Inventory II was predictive of overall quality
of life improvements as well as the performance on the
subscales of emotional well-being and support. The decline
in category fluency was also correlated with a decline in the
communication scale in the STN-DBS group. The overall
impact found by this study, albeit with unilateral DBS, is
an improvement in the quality of life at both target sites,
markedly higher in the GPi-DBS group, affecting the various
domains differently.
Nursing home placement is another component, inti-
mately linked to ability to carry out activities of daily living
and quality of life. A study which followed the long-term
performance of STN-DBS across a span of 10 years found 42%
of their patients were admitted into a nursing home, and this
had a correlation with higher age at the time of surgery [36].
Parkinson disease patients have a higher risk than the general
population to be admitted into a nursing home, linked to their
duration of disease, age, and dementia, but studies have also
shown that nursing home placement is less in DBS treated
patients as compared to medically managed patients alone
(6% versus 15%) [49].
Recently, studies have reviewed the PDQ-39 as the stan-
dard questionnaire used to assess quality of life across the
various disease specific domains. Despite almost universal
usage including our institution, it has its drawbacks. It does
not capture various side effects seen with STN-DSB, such
as apathy, speech difficulties, and impulsive behaviors and
underreports axial symptoms. The PDQ-39 was designed
prior to this data being available and cannot comprehensively
outline the extent or magnitude of benefit or impairment
experienced by the patients. Since apathy plays a major role
8 Parkinson’s Disease
in the patients’ perceptions of benefit, the quality of life scale
ought to include apathy in its computation [47]. It is essential
to have a scale that reflects all the known parameters which
are affected by DBS and to that effect a group has worked to
develop and validate a new deep brain stimulation impair-
ment scale (DBS-IS). The scale consists of 22 questions for 6
subscales, with a high reliability and validity. The subscales
include postural instability and gait difficulties, cognitive
impairment, speaking problems, impulsivity summed score,
and difficulties related to the DBS device. This DBS-IS is not
designed to replace the PDQ-39, rather it is complementary to
it and can assist in DBS candidate selection; for instance, high
preoperative apathy or postural and gait imbalance scores
may caution against the procedure.
At UTSW, the PDQ-39 is measured by the DBS coordina-
tor both prior to surgery and during follow-up visits.We have
not incorporated this new scale in our practice at UTSW and
will probably wait for a refined version which addresses some
of the drawbacks. These limitations include being designed
exclusively with STN-DBS patients, possible missing other
target specific symptoms, as well as being constructed with
patient and care-giver experiences over a period of 1 year
after surgery, which may not accurately represent or capture
the long-term experiences with the DBS procedure [50]. It
is important to note however that this group addresses a
clinically relevant gap and the extensive preoperative testing
and follow-up performed at our institute can incorporate
these parameters.
5.6. Gait and Balance. Improvements in gait and balance
mirror the effects of levodopa in the “on” period, which
is increased by DBS. However, this gain is often lost due
to progression of the disease, possibly hastened by surgery
[40] and lesional effects of the procedure itself. It is vital to
counsel patients on the ineffectiveness of DBS on medication
unresponsive gait and balance issues. At UTSW, automated
gait and balance assessments (in the medication “on” and
“off” phase) using the APDM Mobility Lab (consisting of
up to 6 wireless sensors on the patient, to measure the
various kinetic parameters during predefined tasks such as
walking and turning, which are analyzed using various plug-
ins such as iTUG and iSWAY) provide objective measures
of gait and sway [12]. This testing is carried out both pre-
and postoperatively. A randomized trial at the veteran’s
affairs and university hospitals showed the superiority of GPi
over STN-DBS for gait issues when both medications and
stimulation were off, which lasted for an extended period
(24 months) [16] with conflicting findings in another trial
(NSTAPS) which showed STN-DBS superiority for gait in the
off phase in a post hoc analysis [23]. Experimentation using
DBS at the pedunculopontine nucleus (PPN) as an alternate
management site for gait and balance instability is underway
[51], yet to be performed at UTSW pending stronger safety
and efficacy data.
5.7. Speech and Swallowing. Axial functions such as speech
and swallowing are complex functions and have a direct
relation tomortality (by aspiration) and need to be addressed
for optimal quality of life. A review of the effects of DBS on
swallowing highlights the fact that while most studies suggest
an impairment of swallowing with STN-DBS, there was no
clinically significant impairment or improvement measured,
and studies notably did not compare STN to GPi or unilateral
versus bilateral stimulation [52]. STN-DBS has been reported
to help reduce the vocal tremor in patients with a trade-off
of reduced volume, and DBS induced dysarthria, possibly
due to the spread of stimulation to the corticospinal tract,
ultimately reducing speech intelligibility [20, 53]. At UTSW,
the effects of DBS on these functions are recognized and
their comprehensive assessment is part of the preoperative
work-up for patients. This involves a swallow evaluation and
laryngeal video stroboscopy and performing the Consensus
Auditory-Perceptual Evaluation of Voice (CAPE-V) and the
Voice Handicap Index (VHI-10). This potential deterioration
of speech and swallow functions after DBS is addressed
while counseling patients for the procedure and specific
treatments if possible are instituted before the surgery. Ideally
we would make speech and swallow testing part of the
postoperative work-up to track progress and enable early
detection of deterioration if any, but since we are limited
within the framework of insurance, this testing is performed
postoperatively only in cases with reported adverse events.
5.8. Autonomic Symptoms. Patients with Parkinson disease
often suffer from autonomic symptoms; their response to
DBS remains variable and understudied and mainly in STN
targets. While STN-DBS was thought to impact blood pres-
sure and heart rate, studies have not demonstrated statistical
changes. The positive effect of STN-DBS on constipation is
noted but this is likely to be related to increased patient
mobility. A direct effect of STN-DBS on bladder dysfunction
has been theorized but is not clear [21].
5.9. Sleep. STN-DBS has demonstrated an improvement in
the quality of sleep for patients, with an increase in total
sleep time, time spent in REM, and slow wave sleep as
measured by polysomnography and the PDSS: Parkinson
disease subjective sleep scale. The improvement in scores
was noticed when stimulation was off and can be attributed
in part to the surgical lesioning of the STN nucleus itself.
These effects were related to the extent of motor gains and the
reduction of day time sleepiness due to reduced medications,
thus improving night time sleep quality. The few studies
tracking this data have not shown a difference between the
two sites in sleep benefits [23]. Similarly, there is limited and
conflicting evidence on the effects of STN-DBS on apathy
and fatigue, from mild improvement to worsening, possibly
related to the effects of decreased medication, with a possible
emergence of fatigue as a long-term complication of STN-
DBS [21, 54]. AtUTSW,wehave not incorporated the PDSS or
polysomnography into the DBS program design for outcome
tracking but are open to its utilization pending clinical need.
5.10. Pain. Patients of Parkinson disease experience different
types of pain: musculoskeletal, dystonic, central, radicular,
and somatic, exacerbated during the off period. The relief
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afforded by DBS to motor symptoms such as rigidity and
dystonias is largely responsible for ameliorating the first
2 categories and possibly acting on central pain as well.
A paradoxical effect of body discomfort is observed infre-
quently in patients particularly of STN-DBS as the reduced
blood levels of levodopa result in a decreased pain threshold
[21]. At UTSW, patients’ pain and discomfort are tracked in
the Parkinson Disease Questionnaire-39 (PDQ-39), a self-
assessment of various quality of life parameters including
bodily discomfort.
5.11. Mortality. It is worthwhile to investigate whether the
improvement in quality of life andmotor function in patients
with Parkinson disease has an overall impact on mortality: is
there a change in the natural progression of the disease with
DBS?
Patients with Parkinson’s disease have a higher mortality
than the general population, with an odds ratio of 2.56 and a
5-fold higher chance of being placed in a care facility. So far,
while drug therapies in some studies have shown a positive
influence on the disease when started early on, they have not
yet shown any change in mortality or the ability to prevent
the onset of dementia or falls [55]. On the other hand, a
trial exploring this question demonstrated that patients who
underwent bilateral STN-DBS had significantly longer sur-
vival and were also significantly less likely to be admitted in a
residential care facility (6%) as compared tomatched patients
(15%) who, while eligible for DBS, opted to be managed
medically [49]. Another outcome observed in this studywas a
large cohort of patients in the medically managed group who
died of respiratory causes as compared to theDBS group (20%
versus 2%), likely related to aspiration due to swallowing
impairments. This suggests that improved deglutition is a
benefit of STN-DBS, with a favorable mortality advantage
(albeit this study focuses on a STN target). Another long-
term STN-DBS study (10-year follow-up) demonstrated that
mortality had a 2-fold increase with an older age at the time
of surgery (above 60 years) as well as a 9-fold increase inmen.
Surprisingly, the duration of disease or its severity or response
to medications was not correlated with mortality. A higher
age at surgery was also shown to be associated with increased
nursing home placement [36].
A survival gain with DBS is usually not discussed with
patients while considering them for DBS, information which
should be incorporated into decision-making. At UTSW,
while there is no fixed age cut-off for surgery, it is a factor
discussed while weighing the risk to benefits of DBS in a
particular patient. We have not formally tracked mortality
data on patients who have undergone DBS at our center.
So far two patients with DBS (one STN and one VIM
(ventralis intermedius)) have passed away, but circumstances
around their death involved multiple compounding factors
and cannot be solely attributed to DBS. It is important for
our quality improvement endeavors to have this data to allow
outcomes tracking, and steps to ensure completeness of our
database will be put in place soon.
Armed with the data showing that increased age at
surgery is a risk factor for suboptimal outcomes and evidence
that opting for DBS at an earlier stage of the disease rather
than after exhausting all options is associated with superior
motor and quality of life outcomes [56], a trend is emerging
towards changing the age consideration for DBS surgery. At
UTSW, the average age at surgery is 73 years for STN and
66 years for GPi. It also revises the treatment paradigm and
presents the opportunity to begin consideration for DBS at an
earlier time period. The ability to have a unified transition to
surgical therapeutic options if required is a draw for several
patients with Parkinson disease at UTSW, with in-house
multidisciplinary teams available for seamless coordination
of care.
5.12. Medication Reduction. There is a unanimous find-
ing that medication (measured as levodopa equivalent
dose (LED) or LEDD (levodopa equivalent daily dose)) is
markedly reduced after STN-DBS as compared to a slight
reduction after GPi-DBS. Studies have shown varying reduc-
tions such as 38% for STN-DSB versus 3% for GPi-DBS
[18] or absolute dose reductions of 408mg in the STN-
DBS group versus 243mg in the GPi-DBS group [16] at 2
years after surgery, which, despite slowly increasing by 36
months [17], remains significantly reduced as compared to
baseline. While this is not the primary goal of surgery, this
reduction in medication allows respite for patients suffering
from disabling side effects which affect quality of life such
as orthostatic hypotension, drug-induced dyskinesia, and
fluctuations in “on” and “off” time. The reduction in medi-
cation should be managed cautiously, as a rapid reduction in
certain medications such as dopamine agonists could lead to
dopamine agonist withdrawal syndromes (DAWS).
The assumption that the reduction in medications is
a pure positive effect must be examined, with evidence
highlighting the complex interplay between symptoms, side
effects, target stimulation, and medications. The possible
increased suicidal ideation observed after STN-DBS has
been linked to a reduction in dopaminergic medication [1].
Observations demonstrate the loss of prior positive effects
of STN stimulation in the medication “on” phase especially
for gait and balance, with worsened motor scores at extended
time points (3 years after surgery) as compared to baseline
[17]. This, coupled with the deterioration of motor scores
in STN-DBS patients in the “off-off” (both medications and
stimulation) phase, not seen in GPi-DBS patients which
retain stable scores [57], bolsters the theory of dopaminergic
medication advantage, and not merely disease progression as
a possible explanation for these phenomena. This leads to
various lines of thoughts such as the desirability of medica-
tion reduction in the absence of side effects, the nature of the
relationship between medications and stimulation, whether
STN stimulation interferes with dopaminergic stimulation,
and whether there is an inherent disease modulating effect
of GPi-DBS outside the role played by medications [58].
6. Unilateral Leads
Asymmetrical symptoms are a hallmark of Parkinson disease,
and although uncommon, patients with predominantly uni-
lateral symptoms have the option to undergo a single lead
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placement. A trial to compare the effects of unilateral DBS at
theGPi and STNonmood and cognition (COMPARE) found
no significant difference in motor and cognitive outcomes
between the 2 sites, with differences in verbal fluency noted
in STN-DBS when not in optimal settings [26]. A follow-
up of these patients after 6 months reveals that more than
half (52%) opted for implantation of a second lead for better
management of their motor symptoms. Of the half that chose
to remain with a single lead, two-thirds of them had GPi
implantation. Thus, factors such as STN site lead and a
lower asymmetric score were associated with a higher risk to
convert to a bilateral implantation, in addition to worsened
motor function (high UPDRS III scores), gait dysfunction,
and dyskinesias. A possible explanation for this could be
the different mechanisms of action of the two nuclei. Since
GPi directly suppresses dyskinesias, it may serve to affect
the contralateral side as well and continue to exert effects
even without medication reductions, which makes unilateral
GPi an attractive option for patients with severe one-sided
dyskinesias. Bilateral STN leads are associated with greater
medication reduction than unilateral leads; hence, adequate
control of dyskinesias often requires both leads. Patients with
predominantly unilateral symptoms could achieve motor
control with a single lead, reducing the perioperativemorbid-
ity and side effects associated with bilateral implantation, and
retain the ability to convert to bilateral leads when required
[59].
7. Programming Paradigms at UTSW
Through a systematic process of testing each electrode,
threshold settings are determined which elicit clinical benefit
and adverse effects which are used in future programming.
The stimulation settings are determined by varying voltage
and pulse width along with contact points and occasionally
frequency, all of which require a high level of skill to
optimize thousands of combinations to attain symptom relief,
with minimal DBS side effects. Programming offers the
ability tomanipulate advanced stimulation settings to achieve
best possible outcomes even in cases with suboptimal lead
placement. DBS programming and medication titration are
delicately intertwined and require close monitoring until the
patient experiences a stable and optimal state, a process that
usually takes around 6 months. Following an optimization of
settings, it is usually safe to expect that other Parkinson dis-
ease related effects cannot be managed by tweaking the DBS
settings. It is also possible to anticipate DBS failures, early in
the course of programming, in the case of low thresholds for
adverse effects or unsustained benefits associated with a lead
[1].
8. Surgical Complications and Adverse Events
Most studies and DBS programs track adverse events often
with additional classification into mild, moderate, or severe
to assist in analysis and comparative studies. The source of
these events can be related to surgery, the device, stimu-
lation, and medications or due to the progression of the
disease itself and are not often distinguishable. It is observed
that patients treated by medication alone have a higher
frequency of adverse events overall; however, the patients
with DBS experience a higher frequency of serious adverse
events [10].
Surgical complications include infection (4%), intracra-
nial hemorrhage (4.4%, leading to 1% rate of permanent
neurological deficits), device related problems such as migra-
tion of leads (2.4%) and lead fracture (3%), and seizures
(3.2%) and are consideredmajor or serious events [21].While
the incidence of surgical complications may be considered
equal between GPi and STN, it is theoretically possible that
GPi, with a shorter battery life which may require more
frequent battery changes, predisposes to higher infection
rates. Adverse events were more common in the initial year
after the surgery as compared to the following years, sug-
gesting a favorable long-term safety profile aside from initial
perioperative risks [60]. The Veterans Affairs Cooperative
Studies Program showed no difference between the types
(severity) or frequencies of adverse events at the two target
sites, withmost severe events resolving by the 24-monthmark
[16]. A study of bilateral STN-DBS with a constant current
device demonstrated that while certain side effects such as
fatigue and dysarthria were related to stimulation, others
such as gait dysfunction and dyskinesias were present in the
absence of the leads being activated, indicating a possible
correlation to the surgery and/or tract itself [38]. Another
surgical factor is the tract followed by the DBS lead during
implantation; while it is inherently different for each target, it
plays a role in the development of side effects independent of
the effects of stimulation. A study showed a direct relation
between the overlapping of electrode trajectories with the
caudate nucleus in STN-DBS patients and the decline in
cognition and memory [61]. Optimizing this trajectory and
ensuring accurate lead placement are vital to achieveminimal
side effects.
Certain side effects such as dysarthria were notably
seen in the first 12 months after surgery, implying a rela-
tionship with DBS rather than progression of the disease.
Other such symptoms linked to the DBS include dysphagia,
excessive salivation, blepharospasms, and weight gain [36].
A randomized and blinded trial between the 2 sites noted
the presence of perioperative complications in mood and
cognition predominantly in the STN-DBS group such as
delirium, hallucinations, and anxiety which resolved with
time, but cognitive changes remained persistent [18]. The
impact of DBS on various motor and nonmotor effects,
such as impulse control disorders, depression, and worsening
cognition, has been described in the relevant sections.
As part of the quality improvement initiative at UTSW,
adverse events and complications, either minor or transient,
are recorded to allow for an analysis of trends if any anddevise
improvements by the neuromodulation network meeting.
This analysis is possibly the next quality improvement study
(cycles of plan-do-study-act) which will be undertaken at
UTSW by the movement disorders section in an effort to
continually optimize our outcomes. There were a total of
9 surgical or device related complications in 28 patients
studied, occurring in DBS performed at the STN as well as
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the VIM (ventralis intermedius) nucleus of the thalamus over
the last 2 years [12].
9. DBS Failure
Suboptimal results from the DBS procedure are often labeled
as DBS failures. Factors common to these “failures” include
inadequate presurgical screening, improper patient selection,
incorrectly placed leads, suboptimal programming, battery
failure, and hardware related issues [1]. Patients are likely
to switch their provider and DBS center in the hope of
improved outcomes. Treatment options include optimizing
the programming and medications to manage side effects or
enhance benefits, as well as second surgeries, for correcting
lead location in case of leadmigration or incorrect placement
or placing rescue leads at the other target site, which could be
unilateral or bilateral.
A randomized trial comparing DBS at the 2 sites
(NSTAPS) had 8 patients of GPi-DBS (from a total of 65) who
had to undergo STN-DBS resurgery due to lack of benefits.
Of these 8 patients, 5 had leads placed correctly. Similarly, 1
patient of STN-DBS (from a total of 63) had a unilateral GPi
lead implanted, and one was reoperated to correctly position
the leads [22]. A waning of prior positive response to GPi-
DBS after a few months to years has been noted in several
cases from the 1990s, which may be indicative of a surgical
technique, patient selection, or postoperative management
issue and often lead to surgical implantation of STN leads
[62]. However, for the most part, studies showed long-term
stability of GPi-DBS and STN-DBS [17].The case report from
UTSWon suboptimal tremor control with bilateral STN-DBS
[27] discussed above is an example of DBS failure, due to
improper lead placement.
10. Cost-Effectiveness
Since DBS is an expensive and long-term undertaking, it is
important to discuss the cost-effectiveness of the procedure
and accurately identify patients who will benefit from it
given the risks and benefits. A study using the University
HealthSystem Consortium (UHC) Clinical database found
the average DBS procedure cost to be $39,152 ± $5340 [63],
with the median cost of implantation in 2013 being $34,052 at
UHC-affiliated hospitals.
A study of the cost-effectiveness of DBS with medical
therapy as compared to the best medical therapy (BMT)
using various analytical models from the Medicare payer
perspective, considering a 10-year horizon, found total costs
of DBS to be $130,510 versus $91,026 for BMT, with a gain
of 1.69 QALYs more than BMT, and a total of $23,404 per
QALY, with greater benefit seen in younger age and longer
follow-up [64]. A similar study in the UK pegged this at
m20,678 per QALY gained [65]. The cost of the surgery is
partially offset by the reduction inmedication costs, forwhich
STN-DBS with its drastic reduction shows a higher benefit.
Expensive medication delivery routes such as continuous
intestinal infusions of levodopa show amaximumcost benefit
after surgery. In a randomized, single-blinded clinical trial to
compare the differences between DBS with medical therapy
versus medical management (ODT) in early stage Parkinson
disease, an analysis of the cost savings showed that while
drug costs increased 72% in the ODT group, they declined by
16% in the DBS + ODT group from baseline to 2 years. This
difference resulted in a saving of $7150 per patient with DBS
over the 2 years, which when extrapolated for the long-term
(10 years) resulted in savings of $64,590 [66]. With a longer
battery life likely related to programming characteristics
STN-DBS shows a possible economic advantage with fewer
surgical procedures required for battery changes.
We at UTSWhave not undertaken a cost-benefit analysis,
as costs depend on and vary with differing patients’ insur-
ances which skew the relevant data; however, it is a topic that
will be researched to understand the financial implication of
DBS, for both the patient and the institute.
11. Unanswered Questions
While DBS is widely used in the management of Parkinson
disease, there are several questions that remain open, and the
quest to solve them will hopefully strengthen the success of
DBS in improving the quality of life in patients.
Questions regarding unilateral versus simultaneous bilat-
eral lead implantation and the utility of the staged operations
require further studies to determine benefit one way or
another. The safety of unilateral implantation with concomi-
tant decreased operative adverse effects especially in the
elderly has to be weighed against the possibility of a second
procedure for inadequate benefit and is usually considered in
patients with extreme asymmetry of symptoms.
Issues faced by patients such as gait-freezing and other
axial symptoms not addressed by DBS require studies to
provide potential solutions. Research into stimulating mul-
tiple leads at different locations to address specific DBS and
Parkinson’s related symptoms is underway.
With increasing evidence forDBS at an earlier stage in the
disease for superior outcomes [56], there is a need to define
optimal age range and disease duration to experience the
maximum benefit from this procedure. A recent prospective,
randomized, single-blind clinical trial in early Parkinson dis-
ease (onmedications for 1–4 years only) compared the motor
and quality of life outcomes of the groups on optimal drug
therapy (ODT) versus DBS with ODT. The study revealed
that patients managed medically are 2–5 times more likely to
experience clinically important worsening than the patients
treated with DBS + ODT [67]. These results increase the
options available to patients in the early stages of Parkinson
disease and highlight the need to reexamine the therapeutic
guidelines in place today.
Cases of DBS failures corrected by dual stimulation of
alternate targets, the “rescue leads” as discussed above [28–
30], point to the need for larger trials on the safety and efficacy
of using dual stimulation as a therapeutic option in patients
of single target DBS with inadequate symptom control due
to SAEs or disease progression.This dual stimulation of both
the target sites could also be considered as a potential DBS
treatment strategy from the get-go, based on the symptom
and patient profile, and needs further exploration.
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While a majority of studies have an end point of 24 or 36
months, there are scarce long-term studies that have tracked
patient outcomes over a span of 10 years [36]. With a possible
trend emerging to perform DBS early in the course of the
disease, it is imperative to have multiple studies addressing
the long-term sequelae of DBS, both positive and negative,
and to assess the impact on disease progression. This in
turn may refine the patient and target selection and provide
information for enhanced decision-making, for both patients
and providers while analyzing the risk-benefit ratio.
12. Future Directions
DBS has become standard of care for treating patients living
with Parkinson disease as well as a wide range of other
movement disorders. The aim of research in the field is to
have a clear understanding of the mechanisms of action of
DBS and the physiological and anatomical basis of various
side effects seen, so as to design a DBS process which
will allow patients to achieve maximum control of all their
symptoms (including ones traditionally resistant to DBS)
with minimal side effects to enhance the quality of life.
Research in this field has resulted in several potentially
and therapeutically beneficial outcomes such as expanded
scope, new targets, enhanced surgical techniques allowing
precise target localization and trajectory such as frameless,
and nonmicroelectrode recording techniques, advances in
imaging such as functional and microstructural imaging,
refined hardware design such as constant current devices,
optimized programming sequences, and other cutting-edge
techniques.
Continued research to elucidate themechanisms of action
of DBS at different targets and charting the anatomical
zones and fiber bundles to explain corresponding side
effects observed are important aspects of DBS research
to understand and avoid the neuropsychiatric effects that
accompany this procedure. Refining technical aspects such
as contact selection may provide a solution to avoid these
unintended effects [68]. Advances in stereotactic localization
and imaging havemade it possible to obtain accurately placed
electrodes without patient participation, precluding the need
for “awake” surgeries and allowing patients who are not ideal
candidates for such “awake” procedures to benefit from DBS
performed under general anesthesia, termed “asleep DBS.”
“Asleep DBS” has been studied and shown to be both safe
and effective, affording the patient significant motor benefit
at 6 months after surgery [69], with no significant differences
in the complications, hospital stay, or 30-day readmission
rates as compared to the traditional awake surgery [70]. The
availability of data from a meta-analysis on this question,
showing similar efficacy and lower complications overall
between awake and asleep DBS [71], makes this a viable
option to include in the monthly neuromodulation commit-
tee meetings.
Research into new targets is underway and can potentially
address the gaps in therapy with DBS at the STN and GPi.
Studies on the pedunculopontine nucleus (PPN), chosen
for its anatomic connections with the basal ganglia and
its functional role in motor modulation and locomotion,
demonstrate improvements in gait and balance including
gait-freezing, the results of which are variable and need
to be confirmed through rigorous trials. The PPN poses
surgical access complications and has zones with varying
functions; hence, studies need to address technique as well
as costimulation of other targets [72]. Attempts to address
gait and balance impairments using dual STN and Substantia
nigra pars reticulata stimulation show promising effects on
gait-freezing, with no additional effects on balance, mood,
or cognition, and are being investigated in clinical trials [73].
Stimulation of the intralaminar thalamic complex comprising
the parafascicular and centromedian nucleus is being eval-
uated for possible therapeutic benefit owing to its location
in the basal ganglia circuit and projections to the striatum.
DBS at this location modulates thalamocortical circuits with
a positive effect on tremor [74].
Studies incorporating stimulation of novel targets in addi-
tion to the standard STN or GPi provide a theoretical means
of addressing adverse effects or levodopa unresponsive symp-
toms. Experiments on the reward circuitry could address
issues such as apathy, depression, and possibly other ICDs
[75]. Through discovery of neural networks and rigorous
trials, a possibility ofmultiple electrodes at different targets to
address the various motor and nonmotor symptoms may be
a distinct possibility, which along with real-time closed-loop
programming may provide a dynamic control of a majority
of symptoms, optimizing the patient’s quality of life [20].
13. Conclusion
Deep Brain Stimulation has revolutionized the lives of
patients living with Parkinson disease. The very decision to
undergo the procedure and the choice of the target site are in
essence a series of risk-benefit analyses.This entails balancing
the probability of improved quality of life, relief of tremor,
rigidity and othermotor symptoms, reducedmedications and
their side effects with the possibility of potentially fatal or
disabling surgical complications and other procedure related
adverse effects, such as worsened cognition or other negative
psychiatric outcomes, and changing the extent of impact of
declined verbal fluency. Computing the best outcomes in
these complex scenarios should be done on a case by case
basis, using each patient’s symptom, disease, medical, risk,
and demographic profile along with patient expectations to
reach the optimal management plan. This tailored approach
to selecting the target site for patients undergoing DBS
is the result of years of data from various studies, trials,
and case reports, which allows a DBS team, including the
neuromodulation network at UTSW to anticipate potential
adverse outcomes and plan ahead to circumvent them, for the
best possible results. If a patient has a history of hallucinations
or has diminished cognitive reserve, GPi-DBS may provide
motor benefit without the possibility of cognitive decline,
if patients suffer significant medication related dyskinesias;
STN-DBS can offer relief. In a similar vein, studies have
also helped in planning the lead location and trajectory,
with leads in the ventral zone of the STN, associated with
a greater incidence of adverse effects. This planning and
refining of patient and target selection, surgical trajectory and
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lead localization by imaging or microelectrode recording,
DBS programming, and other hardware parameters have
resulted in optimizing patient outcomes and unlocking the
full potential that DBS has to offer. Research endeavors aim
to continually enhance the DBS process by addressing the
unmet needs and unanswered questions, through expansion
of our knowledge based on the process mechanisms itself,
technological improvements, trials to test or observe the
safety and efficacy of various therapeutic options in DBS, and
other novel ideas.
An indicator of the commitment of a DBS program
towards its patients is the standard it holds itself up to
and the accountability it has towards all its stakeholders. At
UTSW, the quality improvement effort spearheaded by the
movement disorders group in the department of neurology
fulfills these obligations by subjecting various aspects of the
program to a rigorous examination, cycles of plan-do-study-
act, with the intention of ensuring these high standards.
This endeavor has resulted in the design of the current
processes, namely, the neuromodulation network and the
formal structure in place for preoperative assessment and
follow-up. An important element of this program is capturing
data to allow tracking of outcomes and feedback [12]. The
ultimate goal of these data-driven initiatives is to ensure that
the DBS program dynamically processes and incorporates
information to optimize outcomes in an agile environment.
The commitment of the institutional leadership itself towards
the success of the DBS program should be highlighted, as
their financial support for the newly implemented processes
is vital. The combined dedication of all the stakeholders to
ensure the best possible patient outcomes is a testament of
resolving of UTSW towards improving the lives of those
living with Parkinson disease by developing safer and better
DBS paradigms.
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